WO2018073276A1 - Composition cosmétique pour prévenir et/ou traiter une odeur corporelle - Google Patents

Composition cosmétique pour prévenir et/ou traiter une odeur corporelle Download PDF

Info

Publication number
WO2018073276A1
WO2018073276A1 PCT/EP2017/076535 EP2017076535W WO2018073276A1 WO 2018073276 A1 WO2018073276 A1 WO 2018073276A1 EP 2017076535 W EP2017076535 W EP 2017076535W WO 2018073276 A1 WO2018073276 A1 WO 2018073276A1
Authority
WO
WIPO (PCT)
Prior art keywords
corynebacterium
strain
composition
corynebacterium genus
strains
Prior art date
Application number
PCT/EP2017/076535
Other languages
English (en)
Inventor
Ariel Lindner
Edwin Hampton WINTERMUTE
Original Assignee
Universite Paris Descartes
Institut National De La Sante Et De La Recherche Medicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Descartes, Institut National De La Sante Et De La Recherche Medicale filed Critical Universite Paris Descartes
Publication of WO2018073276A1 publication Critical patent/WO2018073276A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants

Definitions

  • the present invention is in the field of cosmetology, particularly in the field of personal hygiene and more particularly to the prevention and/or treatment of body odor. It relates to a cosmetic composition comprising bacteria of at least one strain of Corynebacterium genus and their use for preventing and/or treating body odor.
  • the skin is an ecosystem composed of 1.8 m 2 of diverse habitats with multiple niches that support a wide range of microorganisms, each niche being characterized by an unique microbial community.
  • the primary role of the skin is to serve as a physical barrier, protecting our bodies from potential assault by foreign organisms or toxic substances.
  • the skin is also an interface with the outside environment and, as such, is colonized by a diverse collection of microorganisms.
  • the skin is considered to support a complex microbial ecology, containing persistent resident bacteria, short- term resident bacteria and transient bacteria. Many of these microorganisms are harmless and in some cases they may even provide vital functions.
  • skin microbial composition which varies greatly among different human subjects, also strongly affects the production of human body odors.
  • distinctive odors emanate, in particular, from the underarm (axilla), where a large and permanent population of microorganisms thrives on secretions from the eccrine, apocrine and sebaceous glands.
  • VFAs Volatile Fatty Acids
  • thioalcohols Volatile Fatty Acids
  • C-S carbon- sulphur
  • Biochemical and bioinformatic work has identified specific enzymes sufficient to release mercaptoethanols from skin-secreted precursors, including the dipeptidase TpdA (Emter and Natsch, 2008) and MalY-type C-S lysases annotated as AecD in Corynebacterium (James et al., 2013). These enzymes act to release a range of odorant sulfur compounds including 3-Methyl-3-sulfanylhexan-l-ol and 3-Sulfanylhexan-l-ol. Volatile steroid compounds have also been associated with biotransformation of sweat by corynebacteria (Decreau et al., 2003).
  • 16-androstenes including 5a-Androst-16-en-3a-ol and 5a-Androst-16-en-3-one have been described as strongly sweaty, musky or urinous in odor. High levels of anosmia for these compounds are naturally present in the human population (Amoorse, 1977), suggesting that they may contribute to subjective variation in the perception of body odor.
  • Waste products of aerobic or fermentative carbon metabolism also contribute to the mixture of volatiles present in the axilla.
  • volatile fatty acids produced from lipids present in the sweat by ⁇ -oxidation, an activity attributed to lipid-catabolizing corynebacteria (James et al., 2004).
  • Isovaleric acid is believed to be primarily a product of leucine metabolism in Staphyloccus (Leyden et al., 1981).
  • acetic acid and propionic acid are products of mixed-acid fermentation in many bacteria including Staphylococcus and Propionibacterium. These odorants are likely to be to be produced by multiple mechanisms and bacterial families within the underarm consortium.
  • a stable skin microbiota is involved in host resistance against skin pathogens and with the increasing use of deodorants and products alike, the axillae would be little vulnerable to environmental microbiota.
  • the stability of the skin microbiota has been attributed to factors such as physiological skin pH, relative skin humidity, skin lipid composition, desquamation of the stratum corneum and skin temperature.
  • topical anti-perspirants the first line of body odor improvement
  • sweat is necessary for thermoregulation control, enabling humans to live in different climate zones and sweat glands are distributed throughout the human body.
  • some cosmetics may contain nutrients such as glycerine, amino acids and hydrolysed collagen which can induce a perturbation of the resident microbiota, or they may contain antimicrobials that increase the presence of resistant strains on skin.
  • the inventors surprisingly found that, contrary to many bacteria known to be responsible to bad smell, some bacteria, preferably strain of Corynebacterium genus can be used in cosmetic composition. More preferably, AgaA and TpdA genes are known to be involved in the production of body malodor. The strain B28 isolated by the inventors carries those genes but the inventors surprisingly found that the strain of the present invention is not involved in body malodor. Furthermore, the inventors found that AgaA and TpdA genes sequences are distinct from the previously described sequences. In this way, their chemical activity may also be distinct and they may produce an odor profile which is different and positive.
  • the present invention thus relates to a cosmetic use of at least one strain of
  • Corynebacterium genus for preventing and/or treating body odor is a group consisting of corynebacterium genus for preventing and/or treating body odor.
  • the present invention relates to a cosmetic composition
  • a cosmetic composition comprising bacteria of at least strain of Corynebacterium genus.
  • the protected strains are distinguished by phylogenetic comparison of the 16S rRNA sequence with all other Corynebacterium sequences deposited in the 16S sequence records of the NCBI RefSeq Targeted Loci Project as of March, 2016.
  • the aggregates of isolate B28 are also visible at the level of entire colonies, which do not separate when probed with a loop.
  • FIG. 3 Corynebacterium sp. Isolate B28 shows superior dessication tolerance and shelf stability. The indicated strains were grown to saturation in TSB, then pelleted and dried overnight in a dessication chamber. Following dessication, cells were left at room temperature and in ambient light for the indicated duration. Cell survival was assessed by plating a defined dry weight to count colony forming units (CFUs).
  • CFUs colony forming units
  • C. sp. Isolate B28 retained 50% viability after 10 weeks. This survival rate exceeds that of C. striatum (ATCC 6940) a type strain in the genus.
  • Corynebacterium were inoculated into the indicated store-bought plant milks and incubated at 37 °C for 16 hours. Cell growth was determined by dilution and plating for CFU count. Isolate B28 showed growth in oat milk at levels similar to laboratory standard broth, and was able to grow in all plant milks tested.
  • the term "preventing” means totally eliminating or partially reducing the risk of manifestation of a given phenomenon, i.e., in the present invention, the manifestation of body malodor. "Partial reduction” implies that the risk remains but to a lesser degree than before the implementation of the invention.
  • treating means a total elimination or partial reduction of the manifestation of body malodor.
  • body malodor means an unpleasant body odor which is mainly caused by unsaturated or hydroxylated branched fatty acids such as 3- methyl-2-hexenoic acid, 3-hydroxy-3-methylhexanoic acid, or S-hydroxyalkyl-L-cysteine.
  • the term "effective amount" means a sufficient and necessary amount of the compound under consideration for obtaining the expected effect. Such an amount may be determined by any method known to those skilled in the art, for example by means of preliminary experimental tests.
  • a "bacterial preparation” refers to a preparation comprising bacteria of the present invention.
  • the bacterial preparation according to the invention can be a solid or a liquid preparation. Accordingly, in certain embodiments, the bacterial preparations herein are suspensions of the bacteria of the invention.
  • Such bacterial preparations can comprise bacteria under living form, inactivated form, dead form or lysate.
  • some "inactivated" bacteria are bacteria which is temporarily no longer capable of forming colonies in culture.
  • a "living form” bacteria are bacteria which have a metabolic activity and which is capable of forming colonies in culture.
  • a “dead form” bacteria are bacteria which is no longer capable of forming colonies in culture nor displaying metabolic activity. More specifically it is some inviable bacteria or metabolically inactive.
  • a “lysate” is means an aqueous solution or suspension comprising the bacterial proteins produced by lysis of bacterial cells.
  • a lysate may comprise macromolecules, like DNA, NA, proteins (e.g. enzymes), peptides, carbohydrates, lipids and/or micromolecules, like amino acids, sugars, lipid acids.
  • said aqueous medium is water, physiological saline, plant milk or a buffer solution.
  • a use according to the present invention may also comprise the use of a lysate of at least one Corynebacterium genus, or a fraction thereof, in combination with at least an effective amount of an additional agent, which is intended for preventing and/or treating body odor, preferably intended for regulating and/or inhibiting sweating, for instance an antiperspirant active agent.
  • said additional active agent is intended for decreasing and/or correcting excessive sweat secretion.
  • Said additional active agent can be used in the form of a formulation of deodorant type, especially a stick or an aerosol.
  • the bacteria of the Corynebacterium genus are aerobic gram-positive Actinobacteria.
  • a genus generally contains several bacterial species which can in turn contain several subspecies, varieties and ultimately strains.
  • the strain of the Corynebacterium genus is, for example, selected from the group consisting of Corynebacterium amycolatum, Corynebacterium minutissimum, Corynebacterium striatum, Corynebacterium pseudotuberculosis, Corynebacterium xerosis, Corynebacterium urealyticum, C Corynebacterium glaucum, Corynebacterium jeikeium and Corynebacterium ulcerans.
  • the strain of the Corynebacterium genus according to the invention is preferably a strain naturally existing at the surface of the skin of a human being.
  • strain of Corynebacterium genus means bacteria of the Corynebacterium genus and/or derived products of the strain of Corynebacterium genus.
  • a "derived products” or “fraction” of the strain of Corynebacterium genus means all metabolites obtainable from bacteria of the Corynebacterium genus.
  • bacteria of a strain of the Corynebacterium genus or "bacteria from a strain of the Corynebacterium genus”, it is herein meant bacteria obtained by culture of a strain belonging to the Corynebacterium genus.
  • a fermentation or culture medium is a support which enables the culture and therefore, as appropriate, the growth of cells, bacteria and yeasts.
  • the cells find in this medium the components essential for them to multiply in large number rapidly, but also sometimes elements which will make it possible to favor the growth of a specific bacterial genus.
  • Its composition must therefore meet the nutritive requirements of the microorganism under consideration and necessary for the proliferation thereof. More specifically, the composition of this culture medium: i) cover the needs in terms of mineral ions and growth factors, and provide the carbon and energy source; ii) have a pH close to the optimum pH; and iii) have an optimum ionic strength.
  • Corynebacterium bacteria are initially known to be the main bacteria implied in body malodors. Inventors of the present invention propose a new use for those bacteria as cosmetic agents in order to modulate the skin bacterial community.
  • strains were isolated from an individual with positively perceived body odor. Such strains produce an odor which is positively perceived and/or, while producing no odor, or less odor, they inhibit the growth of bad smelling bacteria.
  • the present invention relates to the cosmetic use of at least one strain of Corynebacterium genus for preventing and/or treating body malodor.
  • strains belonging to the Corynebacterium genus the most relevant strains isolated from individuals with positively perceived body odor have been selected and sequenced.
  • Each of these strains has several advantages compared to standard strains of Corynebacterium. As shown in example, they possess physiologic or metabolic characteristic which are of utmost importance regarding their use in cosmetic applications such as a high adherence to surface, a superior shelf stability and superior growth abilities.
  • the 16S gene of those superior strains have been characterized and sequenced.
  • the sequence of the 16S r NA gene and/or the corresponding transcript sequences can be determined by methods well known by the person skilled in the art.
  • 16S rRNA is a component of the 30S small subunit of prokaryotic ribosomes.
  • the encoding genes are referred to as 16S rDNA and are used in reconstructing phylogenies as they are highly conserved between different species of bacteria. Primers used for the amplification of such sequences before sequencing are well-known by the person skilled in the art. List of such primers can be found in Weisburg et al., 1991.
  • primers listed in table 1 can be used for nucleic acid analysis based on the 16S r NA gene.
  • Corynebacterium sp. B28 have a 16S gene sequence SEQ ID n°3.
  • the tryptic soy medium is particularly composed by Casein (pancreatic digest) 17 g/L, Soya peptone (papaic digest) 3 g/L, Sodium chloride 5 g/L, Dipotassium phosphate 2.5 g/L and Dextrose 2.5 g/L.
  • Corynebacterium sp. B107 have a 16S gene sequence SEQ ID n°4.
  • Corynebacterium sp B132 have a 16S gene sequence SEQ ID n°5.
  • sequence of 16S gene of such Corynebacterium genus strains have a homology of more than 97 % with the sequences SEQ ID n°3, SEQ ID n°4, or SEQ ID n°5.
  • 16S gene of such strains have a homology of more than 98%, more preferably 99%, even more preferably 99.5% with the sequences SEQ ID n°3, SEQ ID n°4, or SEQ ID n°5.
  • the strain of Corynebacterium genus for the cosmetic use of the invention is selected from the group consisting of Corynebacterium B28, Corynebacterium B107 and Corynebacterium B132. More particularly, the strain of Corynebacterium genus for the cosmetic use of the invention possesses the characteristics of the strain deposited according to the Budapest Treaty at the Institut Pasteur (28 rue du Dondel Roux, F-75024 Paris Cedex 15) on June 22, 2016 respectively under the CNCM number 1-5107 or 1-5108 or 1-5109.
  • Isolate C appendicis circular, shiny, Waxy, Butter 2 days 4.2E+08 85% smooth opaque
  • strains with distinct sequences versions of AgaA and/or TpdA should have reduced or altered functionality compared to the previously described versions.
  • Strains with reduced functionality should control body odor by pushing out high functionality strains.
  • Strains with altered functionality will produce altered odor profiles, including pleasant odors.
  • Corynebacterium strains according to the invention carries the genes TpdA and/or AgaA, with said genes TpdA and AgaA having, respectively, an homology of more than 95 % with the sequences SEQ ID n°3, SEQ ID n°4 or SEQ ID n°5.
  • TpdA and AgaA genes of such strains have a homology of more than 96%, more preferably 98%, even more preferably 99% with the sequences SEQ ID n°3, SEQ ID n°4 or SEQ ID n°5.
  • bacterial preparation of Corynebacterium strains according to the invention can encompasses bacteria per se or within a fermentation medium.
  • bacteria when use per se or within a fermentation medium, bacteria may be in living form, inactivated form, dead form, or in the form of a lysate of said bacteria.
  • the bacteria of the Corynebacterium strains according to the invention may be in living form, inactivated form, dead form, in the form of a lysate of said bacteria, or in a combination of said forms.
  • the bacteria of the Corynebacterium genus used in the context of this invention are preferably in living form or inactivated form. Indeed, living form or inactivated form will be able to grow on the skin and thus will have a long lasting effect.
  • Freeze-drying inactivation may be performed using any method known in the field.
  • Said strain of the Corynebacterium genus inactivated by freeze-drying may be replaced in culture.
  • Corynebacterium strain according to the invention is present in the composition or used in lyophilized form.
  • the bacteria of the Corynebacterium genus used in the context of this invention may also be used in dead form.
  • the Corynebacterium strains may be rendered non-viable by heat treatment, sonication, microwave irradiation, gamma irradiation, ultraviolet irradiation, mechanical cell disruption, chemical cell disruption or combinations thereof. Compositions which do not contain viable bacteria are easier to store and to introduce into products.
  • bacteria are described as dead form when no viable cells and/or colony forming units can be detected by classical plating methods.
  • the absence of viable cells can be shown as follows: no visible colony on agar plates or no increasing turbidity in liquid growth medium after inoculation and incubation under appropriate conditions (aerobic for at least 48h).
  • the bacterial preparation comprised within the composition of the present invention, at least 80%, preferably at least 90%, more preferably at least 95%, ideally at least 99.9% of the Corynebacterium strains may be non-viable.
  • the bacterial preparation may have a viable cell count of less than 1000 colony forming units (CFU) per ml, for example less than 200 CFU/ml, for further example less than 10 CFU/ml.
  • the bacterial preparation may be an extract of a fermentation medium of Corynebacterium strains.
  • the Corynebacterium strains may have been at least partially removed from the fermentation medium.
  • the fermentation medium before the at least partial removal of the Corynebacterium strains contains between 10 s and 10 11 colony forming units (CFU) per ml of Corynebacterium strains.
  • bacterial preparation can be the complete culture medium in which the bacteria were grown until after the microbial growth phase having resulted in the use of the nutritive substrates initially present in the culture medium.
  • the expression "complete culture medium” is intended to denote a medium resulting from the culturing process having been used for the growth of the microorganism. Said medium may or may not have undergone an additional manipulation aimed at separating and/or removing all or part of its non-aqueous constituents.
  • the culture medium can be plant milks such as Soy milk, Oat milk, Rice milk, Millet milk.
  • the fermentation broth is suitable for consumption by humans or pets in case of inadvertent ingestion of the composition.
  • This complete culture medium can undergo a cell lysis in order to produce bacterial lysate.
  • the active agent under consideration according to the invention is formed from the lysate of microorganisms and from all or part, in terms of amount, of the culture medium having been used for the culture of said bacterium and in which its cell lysis was consecutively carried out.
  • the active agent formed according to the invention from the lysate contains the cytoplasmic and cytosolic fractions, the cell wall fragments and the metabolites formed and/or released during the cell lysis of said microorganism, and all of the biological entities capable of being generated and released spontaneously by the bacterium during its fermentation process and therefore already present in the fermentation medium before the cell lysis of said bacterium.
  • the bacteria used in the context of this invention may be bacteria from one or more strains of the Corynebacterium genus. When the bacteria come from one or more strains of the Corynebacterium genus, they are strains of the same species and/or strains of different species.
  • the at least one strain of Corynebacterium genus is preferably applied topically.
  • the at least one strain of Corynebacterium genus can be used on most of the moist sites including the umbilicus (navel), the axillary vault, the inguinal crease (side of the groin), the gluteal crease (topmost part of the fold between the buttocks), the sole of the foot, the popliteal fossa (behind the knee) and the antecubital fossa (inner elbow).
  • the at least one strain of Corynebacterium genus is used on the axillary vault.
  • At least one strain of Corynebacterium genus may be applied at a dosage of between 0.001 mg and 1 mg of the least one strain of Corynebacterium genus on a dry basis per 100 cm 2 of skin.
  • Non- limitative example include that the composition may be applied at a dosage of between 1 and 100 mg of the bacterial preparation of Corynebacterium on a dry basis per 100 cm 2 of skin, 1 to 4 times per day.
  • the invention also related to a composition comprising bacterial preparation of the new bacterial strains identified by the inventors.
  • the bacteria of the Corynebacterium genus may be in living form, inactivated form, dead form, in the form of a lysate of said bacteria, or in a combination of said forms.
  • the bacteria of the Corynebacterium genus used in the context of this invention are preferably in living form or inactivated form.
  • the bacteria used in the context of this invention may be bacteria from one or more strains of the Corynebacterium genus. When the bacteria come from one or more strains of the Corynebacterium genus, they are strains of the same species and/or strains of different species.
  • composition according to the invention may comprises at least one strain of Corynebacterium genus carries the genes TpdA and AgaA, and preferably said genes TpdA and AgaA have, respectively, an homology equal or of more than 95 % with the sequences SEQ ID: 1 and SEQ ID: 2, preferably an homology equal or of more than 98 % with the sequences SEQ ID: 1 and SEQ ID: 2.
  • composition of the present invention comprises said Corynebacterium strain is selected from the group consisting of Corynebacterium glaucum B28, Corynebacterium tuberculostearicum B107 or Corynebacterium tuberculostearicum B132.
  • the composition in the present invention may comprises an amount of bacteria belonging to the Corynebacterium genus superior to 0.001 wt.%, ranging from 0.05 to 20 wt.%, from 0.05 to 3 % by weight relative to the total weight of dry extract of said composition.
  • said composition may comprise 100 to 1 000 000 bacterial cell equivalents of bacteria of said strain of the Corynebacterium genus for 100 g of said composition, preferably 10 000 to 100 000 bacterial cell equivalents for 100 g of said composition.
  • concentration can be easily determined by known culture methods.
  • the composition according to the invention is a cosmetic composition.
  • the invention relates to a cosmetic composition comprising bacteria of at least one strain of Corynebacterium genus as an active ingredient
  • the cosmetic composition according to the invention does not comprise any microorganism other than bacteria of the Corynebacterium genus.
  • composition according to the invention may also comprise other microorganisms, for example chosen among the microorganisms useful in the prevention and/or treatment of body malodor.
  • these other microorganisms may be present in the composition in living form, inactive form, dead form, or in lysate form.
  • Corynebacterium strains according to the invention may be mixed with other ingredients to provide a convenient dosage form.
  • the composition according to the invention may further comprise for example texture and wetting agents, fragrance, conservatives or additional active agent.
  • additional active agent may contribute, together with Corynebacterium strains according to the invention, to solve the technical problem from the present invention.
  • an additional cosmetic active agent can be intended to exert a cosmetic care or hygiene effect on the skin.
  • composition according to the invention may also advantageously comprise at least one sugar, such as sucrose.
  • sugar will help the establishment of the Corynebacterium strains according to the invention in the microbial ecosystem of the skin.
  • composition according to the invention may also advantageously comprise at least Butyric Acid, Turanose, Caproic Acid, N-Acetyl-D-Glucosaminitol, Maltotriose, 3-Methyl Glucose, Succinamic Acid, Tween 20, Acetic Acid, Acetoacetic Acid, Propionic Acid, D-Arabinose, Palatinose, D- ibose, L-Arabinose, Dextrin, a-D-Glucose, L-Lactic Acid, Succinic Acid, Sucrose, D-Xylose, Pyruvic Acid, D-Lactic Acid Methyl Ester, D-Glucosamine, D-Mannose, L-Lyxose, 5-Keto-D-Gluconic Acid, 2- Deoxy-DRibose, D-Malic Acid, D,L-Malic Acid, Dihydroxy Acetone, D-Fructose, L-Malic Acid,
  • the composition comprises at least sucrose, tryptophan, sulfate, pyrophosphate, alanine, leucine or combination.
  • the composition according to the invention is preferably suitable for topical application.
  • a composition for topical administration according to the invention may advantageously be formulated in any form that is suitable for skincare, in particular in the form of protective or care creams, milks, pastes, pomades, lotions, gels (for example a semi- solid emulsion in an alcohol base), ointment, deodorant compositions, depilatory creams bath compositions soaps, cleansing bars or aerosol compositions also containing a pressurized propellant (sprays).
  • the support may be of diverse nature depending on the type of composition under consideration.
  • compositions intended for external topical administration they may be aqueous, aqueous-alcoholic or oily solutions, solutions or dispersions of the lotion or serum type, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous phase (O/W) or conversely (W/O), or suspensions or emulsions, of soft, semi-solid or solid consistency, of the cream type, aqueous or anhydrous gels, microemulsions, a nano-emulsion, a microcapsule preparation, microparticles preparation, composition containing a pressurized propellant, vesicular dispersions of ionic and/or nonionic type or wax/aqueous phase dispersion.
  • These compositions are prepared according to the usual methods.
  • the proportion of the fatty phase may range from 5% to 80% by weight and preferably from 10% to 50% by weight relative to the total weight of the composition.
  • the oils, emulsifiers and co-emulsifiers used in the composition in emulsion form are chosen from those conventionally used in the cosmetics field.
  • the emulsifier and the co- emulsifier may be present in the composition in a proportion ranging from 0.3% to 30% by weight and preferably from 0.5% to 20% by weight relative to the total weight of the composition.
  • the fatty phase may represent more than 90% of the total weight of the composition.
  • the formulation intended for topical administration may also contain adjuvants that are customary in the cosmetics field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, screening agents, odor absorbers and colorants.
  • adjuvants that are customary in the cosmetics field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, screening agents, odor absorbers and colorants.
  • the amounts of these various adjuvants are those conventionally used in the field under consideration, for example from 0.01% to 20% of the total weight of the composition. Depending on their nature, these adjuvants may be introduced into the fatty phase and/or into the aqueous phase.
  • mineral oils for instance hydrogenated polyisobutene and liquid petroleum jelly
  • plant oils for instance a liquid fraction of shea butter, sunflower oil and apricot kernel oil
  • animal oils for instance perhydrosqualene
  • synthetic oils in particular purcellin oil, isopropyl myristate and ethylhexyl palmitate
  • unsaturated fatty acids and fluoro oils for instance perfluoropolyethers.
  • fatty alcohols fatty acids, for instance stearic acid and, for example, waxes, in particular paraffin wax, carnauba wax and beeswax.
  • silicone compounds for instance silicone oils and for example cyclomethicone and dimethicone, and silicone waxes, resins and gums.
  • emulsifiers that may be used in the present invention, mention may be made, for example, of glyceryl stearate, polysorbate 60, PPG-3 myristyl ether, silicone emulsifiers such as cetyl dimethicone copolyol, and sorbitan monostearate or tristearate, PEG-40 stearate and oxyethylenated (20 EO) sorbitan monostearate.
  • Hydrophilic gelling agents include carboxylic polymers such as carbomer, acrylic copolymers such as acrylate/alkyl acrylate copolymers, polyacrylamides, polysaccharides, for instance cellulose derivatives such as hydroxyalkyl celluloses and in particular hydroxypropyl cellulose and hydroxyethyl cellulose, natural gums such as guar gum, locust bean gum and xanthan gum, and clays.
  • Lipophilic gelling agents include modified clays, for instance bentones, metal salts of fatty acids, for instance aluminium stearates and hydrophobic silica, or else ethylcellulose and polyethylene.
  • the invention in another aspect, relates to a method for preventing and/or treating body malodors comprising a step of applying on dry skin a cosmetic composition comprising at least one strain of the Corynebacterium genus.
  • this invention also relates to a method intended to balance the proportion of bacteria of the Corynebacterium genus, producing malodors, in the microbiome present at the skin surface, comprising the topical administration of bacteria of at least one strain of the Corynebacterium or a cosmetic composition as defined above, in an healthy individual with body malodors or at risk of having body malodors, preferably at an area of the skin suspected to induce body malodors.
  • a process according to the invention can be carried out, topically, in particular by administration to the axilla of bacteria belonging to Corynebacterium genus as an active agent for preventing and/or treating body malodors, and more particularly of a cosmetic composition as previously defined.
  • a process of the invention via topical administration can comprise the administration of a composition in accordance with the invention, for example in the form of gels, sprays, sera, lotions or creams.
  • a topical cosmetic process according to the invention can be carried out on a daily basis, at a rate of, for example, a single administration per day or one administration twice a day, for example once in the morning and once in the evening.
  • a topical cosmetic process according to the invention can be carried out over a time period ranging from one week to several weeks, or even several months, this period moreover possibly being repeated after periods without treatment, for several months or even several years.
  • the topical administration of a compound according to the invention may be repeated, for example, 2 to 3 times a day or more and generally over an extended period of at least 4 weeks, or even 4 to 15 weeks, with, where appropriate, one or more periods of interruption.
  • the percentages are percentages by weight and the ranges of values written in the form "between . . . and . . . " include the stated lower and upper limits.
  • the method is preferably continued for several days or several weeks after the disappearance of body malodor, possibly with a gradual reduction in the frequency of administration of the cosmetic composition.
  • the cosmetic composition used within the scope of the invention may particularly be used in healthy subjects, typically subjects not exhibiting skin pathologies.
  • Sweat samples were obtained from volunteers at a public event with their consent. Sweat samples were collected with adhesive cotton pads worn under the clothing and against the axilla. Participants were asked to wear the pads during 15 minutes of light exercise (playing tennis on a game console) or for 60 minutes while they explored the museum. Donors were also given a brief questionnaire on lifestyle, diet and deodorant use.
  • Odor evaluation was performed by volunteers from the same population at the same event. Sweat samples were coded by donor and stored in sealed glass vials. Volunteer smellers were asked to evaluate the samples for their intensity and pleasantness on a scale of 0 to 100. Smellers were also able to assign odor descriptors from a list of categories including note (Animal, chemical, spicy, etc.) and evoked mood (Happy, angry, anxious, etc.). Evaluation was double-blind, randomly assigned, and tracked with a custom web platform.
  • Cotton pads from donors were scrubbed in 5 mL of pH-buffered saline solution with 0.1% Triton X- 100. After 5 minutes of agitation (5 minutes with periodic vortexing to detach bacteria), the solution was collected, diluted and plated to isolate single bacterial colonies.
  • DNA extraction was performed by resuspending a single bacterial colony in 50 ⁇ of TE Buffer (1 mM EDTA, 10 mM Tris, pH 8.0) followed by incubation at 95°C for 5 minutes to lyse the cells. Unpurified lysate was used directly for PCR and genetic analysis.
  • a region of the 16S rRNA gene was amplified by polymerase chain reaction (PCR) with the universal primers 27F (SEQ ID n°l) and 1492R (SEQ ID n°2) using a Bio-Rad T100 Thermal Cycler.
  • the amplified region comprises hyper-variable regions VI and V2.
  • a 25 ⁇ PCR mix was prepared containing: 10 ⁇ of Phusion HF Buffer (5X) with 1 ⁇ of dNTPs (lOmM), 0.5 ⁇ of each primer (lOmM), 0.5 ⁇ of Phusion polymerase (5 ⁇ / ⁇ ), 35 ⁇ of nuclease-free water and 1 ⁇ of DNA template.
  • PCR was run under the following conditions: 98 Q for 0.5 min followed by 35 cycles of 98 Q for 10 s, 55 Q for 0.5 min and 72 Q for 1.5 min and a final extension step at 72 Q for 2 min.
  • the amplification process was checked by electrophoresis in agarose gel (1%).
  • PCR products were purified using Promega and quantified with a NanoDrop 2000 Spectrophotometer (Thermo Scientific). The PCR products were directly sequenced. 1.2.3. 16S RNA sequencing
  • PC products were sequenced using the Sanger sequencing method, performed by GATC the commercial sequencing provider.
  • Dessication tolerance was assessed in strains grown to saturation in tryptic soy medium, then pelleted by centrifugation and dried overnight in a dessication chamber. Dessication was performed at room temperature under mild vaccum, with calcium sulfate supplied as a dessicant. No external cryoprotectants or osmoprotectants were added. Following dessication, cells were left at room temperature (15 Q - 25 Q ) and ambient light conditions for 10 weeks. At periodic intervals, a defined dry weight of cells was collected and resuspended in phosphate-buffered saline solution.
  • Viable cells were counted by was assessed by diluting and plating on tryptic soy agar.
  • the isolation workflow used by the inventors follows standard microbiology practices. This method routinely isolates mostly Corynebacterium, as well as significant numbers of Brevibacterium and Micrococcus. More than 1000 Corynebacterium isolates have been isolated and further screened for significant advantages compared to other Corynebacterium strains. Among those strains, three superior strains have been identified: B28, B107 and B132.
  • Figure 1 is a global taxonomy of 107 bacterial skin isolates.
  • the phylogeny was produced from a global alignment of 16s r NA sequences.
  • described strains from the NCBI RefSeq targeted loci project have been included. Isolated strains span the genre of Corynebacterium. The large majority of isolates are close relatives of Corynebacterium tuberculostericum.
  • isolate B28 carries homologs of AgaA and TpdA that are highly divergent from the described isolates C. striatum Ax20 (94% DNA sequence similarity). This high level of divergence supports the claim that B28 and C. striatum Ax20 are phylogenetically distinct.
  • the adherence properties of B28 will support its stable application to the skin and the establishment of a colony in the case of a living preparation.
  • Isolate B28 shows luxuriant growth on standard lab media including LB broth and Tryptic Soy Broth (TSB).
  • TLB Tryptic Soy Broth
  • the strain also grows in unsupplemented plant milks, such as can be bought in a health food store ( Figure 4).
  • strain can be cultured inexpensively at scale. It also means that the strain could be used in a cosmetic formulation including the plant milks as a base.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition cosmétique comprenant des bactéries d'au moins une souche du genre Corynebacterium et leur utilisation pour prévenir et/ou traiter une odeur corporelle.
PCT/EP2017/076535 2016-10-18 2017-10-18 Composition cosmétique pour prévenir et/ou traiter une odeur corporelle WO2018073276A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16020406.1 2016-10-18
EP16020406 2016-10-18

Publications (1)

Publication Number Publication Date
WO2018073276A1 true WO2018073276A1 (fr) 2018-04-26

Family

ID=57184287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/076535 WO2018073276A1 (fr) 2016-10-18 2017-10-18 Composition cosmétique pour prévenir et/ou traiter une odeur corporelle

Country Status (1)

Country Link
WO (1) WO2018073276A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241339A1 (fr) * 2018-06-12 2019-12-19 Rush University Medical Center Compositions et méthodes de traitement de la rhinosinusite chronique
EP4181146A1 (fr) * 2021-11-15 2023-05-17 Tata Consultancy Services Limited Conception d'une composition personnalisée pour neutraliser les mauvaises odeurs cutanées

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057627A (en) * 1972-03-21 1977-11-08 Helmut Anton Stickl Acne preparation for oral administration
FR2700470A1 (fr) * 1993-01-15 1994-07-22 Sederma Sa Nouvelles compositions cosmétiques contenant des bactéries inactivées et/ou des parois bactériennes et leur utilisation.
FR2779345A1 (fr) * 1998-06-03 1999-12-10 Fabre Pierre Dermo Cosmetique Utilisation d'extraits de microorganismes dans des compositions cosmetiques ou pharmaceutiques destinees a inhiber les odeurs corporelles
US20150216914A1 (en) * 2005-09-13 2015-08-06 Basf Se Microorganisms inhibiting the formation of axillary malodor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057627A (en) * 1972-03-21 1977-11-08 Helmut Anton Stickl Acne preparation for oral administration
FR2700470A1 (fr) * 1993-01-15 1994-07-22 Sederma Sa Nouvelles compositions cosmétiques contenant des bactéries inactivées et/ou des parois bactériennes et leur utilisation.
FR2779345A1 (fr) * 1998-06-03 1999-12-10 Fabre Pierre Dermo Cosmetique Utilisation d'extraits de microorganismes dans des compositions cosmetiques ou pharmaceutiques destinees a inhiber les odeurs corporelles
US20150216914A1 (en) * 2005-09-13 2015-08-06 Basf Se Microorganisms inhibiting the formation of axillary malodor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241339A1 (fr) * 2018-06-12 2019-12-19 Rush University Medical Center Compositions et méthodes de traitement de la rhinosinusite chronique
EP4181146A1 (fr) * 2021-11-15 2023-05-17 Tata Consultancy Services Limited Conception d'une composition personnalisée pour neutraliser les mauvaises odeurs cutanées

Similar Documents

Publication Publication Date Title
US10314866B2 (en) Method of reducing the likelihood of skin cancer in an individual human being
AU2011270870B2 (en) Methods and compositions for reducing body odor
WO2018073278A1 (fr) Composition cosmétique pour prévenir et/ou traiter une odeur corporelle
Callewaert et al. Skin microbiome transplantation and manipulation: Current state of the art
KR101398347B1 (ko) 병원성 미생물에 대해 피부를 보호하기 위한 방법 및 수단
CN101163788B (zh) 皮肤治疗组合物
CN103607997B (zh) 用于预防和/或治疗头皮的头皮屑病症的有益活性剂
KR20080045713A (ko) 발 악취 형성을 저해하는 미생물
US11000558B2 (en) Vaginal preparations for maintaining and/or restoring healthy female microbiota
KR102133689B1 (ko) 용암해수 유래 미네랄과 더마바이오틱스 유래 뉴클레오티드의 결합체 제조방법 및 이를 이용한 기능성 더마바이오틱스 화장품 조성물
WO2018073276A1 (fr) Composition cosmétique pour prévenir et/ou traiter une odeur corporelle
KR102134820B1 (ko) 항균 활성을 갖는 락토바실러스 파라카세이 아종 톨러란스 sw1 균주 및 이의 용도
US20220168208A1 (en) Microbial enzymes to reduce malodour of skin and textiles
TW202220681A (zh) 皮膚細菌叢改善劑及皮膚細菌叢改善用皮膚外用劑
WO2020096059A1 (fr) Agent externe pour la pousse des cheveux ou la prévention de la perte des cheveux
JP6746091B2 (ja) 皮膚外用剤
KR102606325B1 (ko) 락토바실러스 플란타럼 q1 균주를 함유하는 피부 유해균에 대한 항균 및 피부 질환 개선용 조성물
WO2023148428A1 (fr) Utilisation d'ingrédients à base de plantes nordiques permettant de soutenir un microbiome cutané sain
Park Influence of Chemical-and Natural-Based Lotions on Bacterial Communities in Human Forearm Skin
CN101283086A (zh) 抑制形成脚臭的微生物
IT202000013933A1 (it) Ceppo batterico con proprietà antiinfiammatorie
Ouwehand A novel thiol functionalized periodic mesoporous organosilica as adsorbent and bifunctional catalyst
Willmott et al. Investigating the Association Between Nitrate Dosing and Nitrite Generation by the Human Oral Microbiota in Continuous Culture
KR20220022276A (ko) 벌노랑이속 식물의 종자 발효물을 포함하는 액취증의 예방 또는 개선용 조성물
Meunier Combatting body odor by the means of microbial transplantations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17793600

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17793600

Country of ref document: EP

Kind code of ref document: A1